“Mounjaro® KwikPen™ 12.5 mg is an advanced-strength dose intended for patients with severe insulin resistance or those requiring additional therapeutic benefit after the 10 mg dose. It offers enhanced metabolic and weight-loss support under medical supervision.

This strength provides a higher level of receptor activation, resulting in improved glucose utilization, sustained satiety, and further reduction in body weight. Patients at this dose often experience meaningful improvements in overall metabolic markers.

The 12.5 mg KwikPen maintains the same easy-to-use injection system, making it suitable even at higher dose levels.”